血浆置换联合血液滤过治疗抗结核药物所致亚急性肝衰竭的效果分析

侯环荣; 尚佳; 康谊; 李玉魁; 曾艳丽; 丁岗强; 毛重山; 肖二辉

doi:10.3969/j.issn.1001-5256.2016.02.030

血浆置换联合血液滤过治疗抗结核药物所致亚急性肝衰竭的效果分析

DOI: 10.3969/j.issn.1001-5256.2016.02.030

河南省人民医院感染性疾病科

基金项目:

河南省医学科技攻关项目(201303120)；国家临床重点专科建设项目；

详细信息

中图分类号: R575.3
计量
- 文章访问数: 1640
- HTML全文浏览量: 62
- PDF下载量: 369
- 被引次数: 0
出版历程
- 收稿日期: 2015-07-28
- 出版日期: 2016-02-20

Clinical effect of plasma exchange combined with hemofiltration in patients with subacute liver failure induced by antitubercular agents

Department of Infectious Diseases,Henan Provincial People's Hospital

Research funding:

摘要

摘要:
目的探讨血浆置换（PE）联合血液滤过（HF）治疗抗结核药物所致亚急性肝衰竭（SALF）的临床疗效。方法收集2009年7月-2015年1月于河南省人民医院就诊的抗结核药物所致SALF患者58例,按治疗方法不同将其分为PE治疗组（n=27）和PE联合HF治疗组（n=31）。比较治疗前后两组患者的临床症状及体征、肝功能、肾功能、电解质和凝血功能的变化,观察两组患者不良反应发生情况及半年存活率。计量资料组间比较采用t检验,计数资料组间比较采用χ2检验。结果 PE治疗组和PE联合HF治疗组经治疗后,ALT、AST、TBil、GGT、ALP水平较治疗前均降低,凝血酶原活动度（PTA）均升高,治疗前后差异均有统计学意义（t值分别为2.871、2.986、2.905、2.063、4.028、-2.591;2.940、2.935、2.940、2.918、4.981、-2.933,P值均<0.05）;两治疗组间ALT、AST、TBil、GGT、ALP、PTA变化的差值比较差异均有统计学意义（t值分别为-2.891、-2.784、-2.194、-3.014、-0.294、-3.907,P值均<0...
- 肝功能衰竭 /
- 血浆置换 /
- 血液滤过 /
- 对比研究
Abstract:
Objective To investigate the clinical effect of plasma exchange( PE) combined with hemofiltration( HF) in the treatment of subacute liver failure( SALF) induced by antitubercular agents. Methods A total of 58 patients with SALF induced by antitubercular agents who visited Henan Provincial People's Hospital from July 2009 to January 2015 were collected and divided into PE treatment group( 27patients) and PE- HF combined treatment group( 31 patients) according to different therapeutic methods. The changes in clinical symptoms and signs,liver function,renal function,electrolytes,and coagulation function after treatment were investigated and compared between the two groups,and the incidence of adverse events and 6- month survival rate were observed in both groups. The t- test was applied for comparison of continuous data between groups,and the chi- square test was applied for comparison of categorical data between groups. Results After treatment,both PE treatment group and PE- HF combined treatment group had significant reductions in the levels of ALT,AST,TBil,GGT,and ALP,as well as a significant increase in prothrombin activity( PTA)( t = 2. 871,2. 986,2. 905,2. 063,4. 028,- 2. 591,2. 940,2. 935,2. 940,2. 918,4. 981,and- 2. 933,all P < 0. 05); the PE- HF combined treatment group had significantly greater reductions in ALT,AST,TBil,GGT,and ALP and a significantly greater increase in PTA,as compared with the PE treatment group( t =- 2. 891,-2. 784,- 2. 194,- 3. 014,- 0. 294,and- 3. 907,all P < 0. 05). In the PE treatment group,the response rates to correct high urea( UREA),high creatinine( Cr),hypokalemia,hyponatremia,hypochloridemia,and hypocalcemia were 80. 00%,60. 00%,81. 82%,78. 57%,88. 89%,and 75. 00%,respectively; in the PE- HF combined treatment group,these response rates were 85. 71%,87. 50%,85. 71%,92. 31%,92. 31%,and 86. 67%,respectively; there were significant differences in these response rates between the two groups( χ2= 9. 603,11. 302,9. 543,13. 987,9. 493,and 9. 502,all P < 0. 05). The PE treatment group had an overall response rate of88. 89% and a mean hospital stay of 36. 36 days,while the PE- HF combined treatment group had an overall response rate of 96. 77% and a mean hospital stay of 26. 03 days; the incidence rates of adverse events in these two groups were 5. 06% and 7. 06%,respectively. Conclusion As for the treatment of SALF induced by antitubercular agents,compared with PE treatment alone,PE combined with HF can significantly relieve patients' clinical symptoms and signs,improve liver function,correct electrolyte disturbance,improve renal function,increase overall response rate,and reduce the mean hospital stay,and has a lower incidence rate of adverse events. Therefore,it is an effective and safe therapeutic method.
- liver failure /
- plasma exchange /
- hemofiltration /
- comp study

HTML全文

参考文献(15)

[1]SHIZUMAS T,FUKUYAMA N.Investigation into bacteremia and spontaneous bacteria peritonitis in patients with liver cirrhosis in Japan[J].Turk J Gastroenterol,2012,23(2):122-126.

[2]WANG YY,HUANG JR.Research advances in artificial liver for treatment of liver failure[J].J Clin Intern Med,2014,31(8):509-512.(in Chinese)王银银,黄建荣.人工肝治疗肝衰竭研究进展[J].临床内科杂志,2014,31(8):509-512.

[3]Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,Chinese Medical Association;Severe Liver Diseases and Artificial Liver Group,Chinese Society of Hepatology,Chinese Medical Association.Diagnosis and treatment of liver failure[J].Chin J Hepatol,2006,14(9):643-646.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝治疗组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14(9):643-666.

[4] Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,CMA.Guidelines for treatment of liver failure by non-bioartificial liver support system(2009)[J].Chin J Clin Infect Dis,2009,2(6):321-325.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝学组.非生物型人工肝支持系统治疗肝衰竭指南[J].中华临床感染病杂志,2009,2(6):321-325.

[5]PRASAD R,GUPTA N,SINGH M.Multidrug resistant tuberculosis:trends and control[J].Indian J Chest Dis Allied Sci,2014,56(4):237-246.

[6]DHEDA K,GUMBO T,GANDHI NR,et al.Global control of tuberculosis:from extensively drug-resistant to untreatable tuberculosis[J].Lancet Respir Med,2014,2(4):321-338.

[7]GNTHER G.Multidrug-resistant and extensively drug-resistant tuberculosis:a review of current concepts and future challenges[J].Clin Med,2014,14(3):279-285.

[8]BABALIK A,ARDA H,BAKIRCI N,et al.Management of and risk factors related to hepatotoxicity during tuberculosis treatment[J].Tuberk Toraks,2012,60(2):136-144.

[9]RAMAPPA V,AITHAL GP.Hepatotoxicity related to anti-tuberculosis drugs:mechanisms and management[J].J Clin Exp Hepatol,2013,3(1):37-49.

[10]GAUDE GS,CHAUDHURY A,HATTHOLI J.Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients[J].J Family Med Prim Care,2015,4(2):238-243.

[11]CHANG KC,LEUNG CC,YEW WW,et al.Hepatotoxicity of pyrazinamide:cohort and case-control analyses[J].Am J Respir Crit Care Med,2008,177(12):1391-1396.

[12]LI LJ,ZHANG YM,LIU XL,et al.Artificial liver support system in China:a review over the last 30 years[J].Ther Apher Dial,2006,10(2):160-167.

[13]LI MQ,TI JX,ZHU YH,et al.Combined use of non-biological artificial liver treatments for Patients with acute liver failure complicated by multiple organ dysfunction syndrome[J].World J Emerg Med,2014,5(3):214-217.

[14]RIKKER C.Liver support systems today[J].Orv Hetil,2009,150(51):2299-2307.

[15]WEI ZW.Plasma exchanges in treatment of patients with antitubercular agent-induced subacute hepatic failure[J].J Pract Hepatol,2014,17(3):315-316.(in Chinese)韦贞伟.血浆置换治疗抗结核药物导致的亚急性肝衰竭患者23例[J].实用肝脏病杂志,2014,17(3):315-316.

施引文献

资源附件(0)

访问统计